Relevant bibliographies by topics / Captopril

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Captopril'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Captopril.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Captopril"

1

Zucker, I. H., J. S. Chen, and W. Wang. "Renal sympathetic nerve and hemodynamic responses to captopril in conscious dogs: role of prostaglandins." American Journal of Physiology-Heart and Circulatory Physiology 260, no. 1 (January 1, 1991): H260—H266. http://dx.doi.org/10.1152/ajpheart.1991.260.1.h260.

Full text
Abstract:
The angiotensin converting enzyme inhibitor captopril has been shown to cause resetting of the arterial baroreflex to a lower pressure without a change in gain. The present study was conducted to determine whether captopril altered the relationship between arterial pressure, heart rate, and renal sympathetic nerve activity in conscious quietly resting dogs. Fourteen instrumented dogs were given 2 mg/kg iv of captopril; 10 min later postcaptopril measurements were made. Six of the fourteen dogs were pretreated with cyclooxygenase inhibitor (indomethacin or meclofenamate) before administration of captopril. Renal nerve activity and hemodynamics were measured in a final group of eight dogs in which arterial pressure was lowered with a graded infusion of sodium nitroprusside. Captopril caused a small but significant decrease in arterial pressure. This decrease in arterial pressure was accompanied by a significant increase in heart rate; however, renal sympathetic nerve activity was significantly reduced. In contrast, dogs receiving nitroprusside exhibited an increase in both heart rate and renal sympathetic nerve activity in response to similar decreases in arterial pressure. Dogs that received cyclooxygenase inhibitor showed reduced arterial pressure in response to captopril, increased heart rate, and increased renal sympathetic nerve activity. This study is the first to report a decrease in sympathetic nerve activity in response to captopril in an awake chronically instrumented animals. These data suggest that captopril's ability to augment prostaglandin synthesis is responsible for the observed sympathoinhibition.
APA, Harvard, Vancouver, ISO, and other styles
2

Sastrosubroto, Hardiman, Santosa Soeroso, and Eriyati Indrasanto. "Captopril Treatment in Rheumatic Heart Disease with Congestive Heart Failure A Preliminary Report." Paediatrica Indonesiana 29, no. 9-10 (March 20, 2018): 209–14. http://dx.doi.org/10.14238/pi29.9-10.1989.209-14.

Full text
Abstract:
A small scale controlled trial of captopril (ACE inhibitor) was conducted in 8 children with congestive heart failure due to rheumatic mitral regurgitation with or without mild mitral stenosis. The age of the patient ranged from 5.5 to 13 years (mean 9,3 years). Four children, served as control group, received digitalis and diuretics as standard treatment; while the other 4 children also received 2 x 12,5 mg of captopril in addition to standard treatment. The effect of both regimens were measured by usingchanges of left ventricular function as seen on the echocardiogram performed before treatment, and then 3, 7 and 14 days thereafter. Definite conclusion cannot be made because of the small number of patients; but it is apparent that some improvements of left ventricular functions in the captopril group were more evident when compared with that of the control group of standard treatment.Side effects of captopri/ were not found.
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Captopril." Reactions Weekly &NA;, no. 1393 (March 2012): 12. http://dx.doi.org/10.2165/00128415-201213930-00035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

&NA;. "Captopril." Reactions Weekly &NA;, no. 722 (October 1998): 7–8. http://dx.doi.org/10.2165/00128415-199807220-00012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Captopril." Reactions Weekly &NA;, no. 727 (November 1998): 7. http://dx.doi.org/10.2165/00128415-199807270-00017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Captopril." Reactions Weekly &NA;, no. 733 (January 1999): 7. http://dx.doi.org/10.2165/00128415-199907330-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Captopril." Reactions Weekly &NA;, no. 1152 (May 2007): 8. http://dx.doi.org/10.2165/00128415-200711520-00024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

&NA;. "Captopril." Reactions Weekly &NA;, no. 1364 (August 2011): 12. http://dx.doi.org/10.2165/00128415-201113640-00044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

&NA;. "Captopril." Reactions Weekly &NA;, no. 535 (January 1995): 5. http://dx.doi.org/10.2165/00128415-199505350-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Captopril." Reactions Weekly &NA;, no. 539 (February 1995): 5. http://dx.doi.org/10.2165/00128415-199505390-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Captopril"

1

Coelho, Marcelle Castro. "Estudo do impacto do descarte dos comprimidos de captopril no meio ambiente." Universidade do Estado do Rio de Janeiro, 2014. http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=6745.

Full text
Abstract:
O Captopril é um dos medicamentos anti-hipertensivos mais consumidos no Brasil. Constitui-se em um pó cristalino, branco ou levemente amarelado, com leve odor característico de sulfeto, facilmente solúvel em água, etanol, clorofórmio e metanol. Em soluções aquosas, o captopril sofre reação de oxidação, formando em quantidade crescente como produto de degradação o dímero dissulfeto de captopril. Além disso, no período de 24 horas, mais de 95% da dose absorvida é eliminada pela urina, sendo 40 a 50% na forma inalterada, e o restante na forma do dímero dissulfeto de captopril e de outros metabólitos, os quais são encaminhados para o esgoto, podendo assim atingir os corpos dágua. O presente trabalho foi planejado de maneira a estudar o impacto e o comportamento do medicamento e do seu produto de degradação em águas ambientais. Para isso, foi feita a validação do método analítico escolhido, cromatografia líquida de alta eficiência, que foi a ferramenta adequada para garantir a confiabilidade dos dados analíticos do método. Foi monitorada também a estabilidade do fármaco na forma de comprimidos e em solução aquosa, ao longo de 144 dias. Os resultados mostraram que quando os comprimidos de captopril são armazenados em sua embalagem original, nesse caso blister, a uma temperatura controlada igual a 40o C e umidade controlada igual a 75 %, eles permaneceram estáveis. A concentração de captopril apresentou uma média igual a 97,4 %. Por outro lado, quando diluído e armazenado nas mesmas condições de temperatura e umidade citadas anteriormente para a obtenção de uma solução aquosa na concentração igual a 1 mg/mL, a substância captopril chegou a variar de 95,7% a 68,5%. Já o seu produto de degradação, dissulfeto de captopril, atingiu um aumento na concentração de 1,7 para 31,1%, ambos em 144 dias
Captopril is one of the widely used anti-hypertension remedies used in Brazil. It is a crystalline white or slightly yellow powder, with a typical sulfide odor, easily soluble in water, ethanol, chloroform and methanol. In aqueous solutions, captopril tends to oxidize, producing growing concentrations of its degradation product, the dimmer captopril disulfide. Beyond this, in the period of 24 hours, more than 95% of the absorbed dose is excreted in the urine, 40 to 50% of the component in its original form, and the remaining in the form of captopril disulfide and other metabolites, which are discharged in the domestic waterstreams, reaching other waterbodies. Thus, the present work was planned to study the impact and the behavior of this remedy and its degradation product in environmental waters. To reach this goal, initially the validation of the analytical method selected to quantify its degradation was performed, high efficiency liquid chromatography, a suitable tool to guarantee reliability to analytical data. The stability of the pharmaceutical product, in the form of tablets, as well as in aqueous solutions, during 144 days. The results indicated that captropril tablets when stored in its original package, blister, to a controlled temperature of 40o C and 75% relative humidity, were kept stable. The average captopril concentration was equal to 97.4%. On the other hand, when diluted and stored in the temperature and relative humidity mentioned before, for a 1 mg/mL concentration, the substance captopril ranged from 95.7 to 68.5%. Its degradation product, captopril disulfide, increased from 1.7 to 31.1%, in around 144 days
APA, Harvard, Vancouver, ISO, and other styles
2

Park, Sean, Basil Wong, and David Lee. "Stability of Extemporaneously Prepared Captopril Solution." The University of Arizona, 2012. http://hdl.handle.net/10150/614512.

Full text
Abstract:
Class of 2012 Abstract
Specific Aims: Assess the stability and sterility of various extemporaneously compounded captopril solution in different storage conditions. Methods: Extemporaneously prepared captopril standards and solutions tested in a high performance liquid chromatography instrument collected data on stability. In addition, physical appearance, bacterial growth and pH data were also collected. Main Results: Stability data was assessed with extemporaneously prepared captopril solutions prepared with standardized captopril powder, captopril tablets and captopril tablets with ascorbic acid included. Stability was defined as retention of at least 90% of the initial captopril concentration. Overall, all preparations were stable when stored at 4°C but only the tablet preparation was stable when stored at 25°C and 40°C. No bacterial growth was observed with any of the captopril solutions. Conclusions: Extemporaneously prepared captopril solution appears to have a shelf-life of at least 28 days when stored at 4°C.
APA, Harvard, Vancouver, ISO, and other styles
3

LUNEAU, MARIE-BENEDICTE, and HENRI CARRERE. "La lithiase cystinique : role therapeutique du captopril." Lille 2, 1993. http://www.theses.fr/1993LIL2M108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hunsinger, Chantal. "L'association furosémide - captopril chez les insuffisants cardiaques hyponatrémiques." Strasbourg 1, 1988. http://www.theses.fr/1988STR15073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Porche, Mya. "Spectrophotometric Determination of Nitrite by Derivatization with Captopril." Miami University / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=miami1399075201.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mhaka, Farai Arthur. "Development and manufacture of sustained release captopril beads." Thesis, Rhodes University, 2015. http://hdl.handle.net/10962/54712.

Full text
Abstract:
Hypertension has a high mortality rate in developing countries such as South Africa. Although the prevention and control of hypertension is a health priority, efforts to decrease the global burden of hypertension and improve control over the condition are inadequate. The use of angiotensin converting enzyme (ACE) inhibitors such as captopril (CPT) have been effective for the management of hypertension when used as first line therapy alone or in combination. Commercially available immediate release dosage forms containing 12.5, 25 and 50 mg of CPT are administered two or three times a day to treat hypertension. CPT degrades in aqueous media with the sulfhydryl functional moiety responsible for adverse effects such as hypersensitivity, taste disturbances and/or presenting with a dry hacking cough. CPT has a short elimination half-life of between 1.6 and 1.9 hours, which means that the compound is a suitable candidate for inclusion in sustained release (SR) dosage forms. Manufacturing a SR dosage form of coated beads for twice daily dosing may reduce the incidence and intensity of undesirable adverse effects, improve the stability of CPT and improve patient adherence. A stability indicating reversed-phase high performance liquid chromatographic (RP-HPLC) method was developed and optimised using a central composite design approach. As part of this approach the interactive effects of input factors, viz. pH, methanol (MeOH) content and column temperature on retention time, were investigated to achieve a separation with well-resolved and symmetrical peaks for CPT and salicylic acid. The method was validated using ICH guidelines and was found to be simple, linear, precise, accurate, selective and rapid for the in vitro quantitation of CPT. The method was successfully applied for the analysis of both commercially available and test formulations. Preformulation studies were undertaken to establish the physical and chemical properties of CPT, excipients and dosage forms to ensure the production of stabile and bioavailable products. Powder blends were assessed for flow properties using angle of repose (AOR), and bulk and tapped density, which were subsequently used to calculate Carr’s Index (CI) and the Hausner ratio (HR). The addition of talc resulted in the most powder blends with AOR, CI and HR that were within a range indicative of satisfactory to good flow properties. The use of talc was necessary to ensure that blending prior to wet granulation and extrusion-spheronisation would produce homogenous powders. Thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and Fourier Transform Infrared Spectroscopy (FT-IR) were used for the identification and purity of CPT alone and 1:1 binary mixtures with excipients in an effort to establish if CPT was likely to undergo physical and/or chemical modification during production. The DSC thermograms for all CPT-excipient mixtures revealed the presence of a melting endotherm that was wider, occurring at 110.93 °C (Tpeak for pure CPT). The characteristic peaks for specific functional groups were present in the FT-IR spectra for powder mixtures, indicating the absence of incompatibilities. Dialysis studies were used to investigate if the ammonium oleate present in Surelease® E-7-19010 interacted with CPT. The results suggests that an interaction between CPT and Surelease® E-7-19010 during processing of CPT beads was unlikely to occur. Preliminary investigations reveal that Methocel® K100M, Methocel® E4M, Avicel® PH102, Eudragit® RS PO, Surelease® E-7-19010 and talc are compatible with CPT and could be used for the manufacture of SR CPT beads. CPT beads were manufactured using extrusion-spheronisation and coated using a fluidised bed drier fitted with a Wurster insert. The amount of granulating fluid, coating levels, curing time and formulation composition were varied to achieve CPT release with specific criteria to develop a preliminary formulation. The coated beads met all desired quality attributes in respect of micromeritic and flow properties, content uniformity and friability. Response Surface Methodology was used to further optimise the SR CPT formulation. The Plackett-Burman design was used for this process to produce an SR dosage form with desirable quality attributes achieved by altering formulation composition, extrusion-spheronisation variables and coating parameters. ANOVA data revealed significant responses for yield, aspect ratio, sphericity, coating efficiency and cumulative percent CPT released at 2 and 12 hours. Formulations in which the high molecular weight HPMC were used in increased concentrations resulted in the formation of a sticky wet mass and extrudate, resulting in a decrease in yield. The application of a permeable, but insoluble Surelease® coat onto the surface of the beads formed a barrier that complements the activity of the hydrophilic matrix in preventing rapid dissolution and retarding the release of CPT from the beads. The amount of CPT released over 12 hours revealed that increasing the Methocel® K100M content entrapped CPT and retained it more efficiently in the hydrated matrix, resulting in a slow rate of CPT release. In vitro release data were fitted to a number of models in an attempt to elucidate mechanistic aspects of transport processes specific to CPT from the coated bead formulations. The results of fitting data from optimised batches revealed that the goodness of fit based on the adjusted correlation coefficient ranged between 0.953 and 0.976 for the Higuchi model, indicating that diffusion is a predominant factor that controls CPT release from the coated beads. The results of fitting data to the Korsmeyer-Peppas model suggest that the mechanism of CPT release includes transport of the dissolution medium from the vessel reservoir into the core of the bead due to osmotic potential, dissolution of CPT, mass transfer of the dissolved CPT within the core, partitioning between the solution and polymeric film, mass transfer of dissolved CPT through the film to ultimately reach the bulk dissolution fluid. A SR CPT bead formulation that has potential for further development and optimisation for scaled-up production using RSM approaches and Design of Experiments such as CCD or Box-Behnken has been successfully developed and manufactured using extrusion, spheronisation and coating processes. Assessment of all batches of beads manufactured exhibited satisfactory to good flow properties and demonstrated SR profiles over 12 hours that met USP criteria for SR dosage forms.
APA, Harvard, Vancouver, ISO, and other styles
7

Dalton, Geoffrey Richard. "The effect of regression of left ventricular hypertrophy on gene expression, cellular properties of isolated cardiac myocytes and cardiac arrhythmias." Thesis, University of Bristol, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.389034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

CHUPIN, ROGER PHILIPPE. "Etude comparative de la prise sublinguale et de la prise orale pour le test au captopril dans l'exploration de l'hypertension arterielle." Angers, 1988. http://www.theses.fr/1988ANGE1115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Yim, Cynthia. "Effects of ovokinin on isolated aortas of guinea pigs, normotensive and spontaneously hypertensive rats." Thesis, Virginia Tech, 1998. http://hdl.handle.net/10919/36796.

Full text
Abstract:

Ovokinin, a peptide recently isolated from an enzymatic digest of ovalbumin, has been shown to mediate vasorelaxation of the canine mesenteric artery through bradykinin B1 receptors. Bradykinin can mediate both vasorelaxation and vasocontraction depending upon the tissue or species investigated. The aim of this study was to characterize ovokinin further by determining whether the effects of this peptide, like bradykinin, vary when using different species and tissue preparations as well as different contracting agents. Isolated aortic rings from guinea pigs, normotensive rats, and spontaneously hypertensive rats were exposed to phenylephrine, prostaglandin F2a, potassium chloride, or bradykinin. Bradykinin contracted guinea pig and spontaneously hypertensive rat aortas, however, it had no effect on normotensive rat aortas. In this study, ovokinin did not exhibit activity in any of the preparations except in guinea pigs, where it potentiated the contraction elicited by bradykinin only. This potentiation was blocked when rings were pretreated with captopril, a kininase II inhibitor. Ovokinin may also exhibit slight vasorelaxing activity in spontaneously hypertensive rat aortas precontracted with prostaglandin F2a. These findings suggest that, like bradykinin, the effects of ovokinin are species- and tissue-dependent. The action of ovokinin on the guinea pig aorta may involve kininase II, which is partly responsible for the degradation of bradykinin and other kinins.


Master of Science
APA, Harvard, Vancouver, ISO, and other styles
10

Saurí, Duran Jaume. "Desenvolupament i caracterització de comprimits matricials hidròfils de captopril." Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/316030.

Full text
Abstract:
L’objectiu de la tesi doctoral ha estat el desenvolupament i la caracterització de comprimits matricials hidròfils de captopril. Actualment no existeix una forma farmacèutica d’alliberació modificada de captopril en el mercat, ja que el captopril és inestable al pH bàsic intestinal. La inestabilitat en l’intestí, juntament amb l’elevada solubilitat en aigua que presenta, fa que el captopril sigui un principi actiu molt difícil de formular en sistemes d’alliberació modificada. Com a conseqüència de la recerca bibliogràfica realitzada, en aquesta tesi doctoral s’han elaborat uns sistemes matricials per compressió directa que es retinguin a l’estómac per tal d’assegurar una òptima estabilitat durant l’alliberació del captopril. La recerca del treball ha consistit en l’elaboració de formulacions amb diferents perfils de dissolució aplicant la metodologia Quality by Design (QbD), i la seva caracterització mitjançant el diagrama SeDeM i tècniques microscòpiques, les quals han estat utilitzades per primer cop en la caracterització de matrius hidròfiles. La metodologia utilitzada ha estat la combinació d’una recerca bibliogràfica molt exhaustiva, que juntament amb l´ús de tècniques microscòpiques avançades (Microscòpia de Força Atòmica, Microscòpia Electrònica de Rastreig, Angle de Contacte, i Microscòpia Confocal), s’han relacionat els paràmetres fisicoquímics de les matrius hidròfiles amb els paràmetres microscòpics. Els resultats de la recerca han estat l’obtenció d’unes metodologies que suposen un avenç científic en la caracterització de matrius hidròfiles. Els resultats obtinguts en aquesta tesi doctoral poden donar lloc a un ampli ventall d’estudis en el camp de la Tecnologia Farmacèutica, ja que els conceptes adquirits són potencialment aplicables en altres sistemes d’alliberació de fàrmac
The aim of the thesis has been the development and characterization of hydrophilic matrix tablets of captopril. Currently, there is no any modified release dosage form of captopril in the market, since captopril is unstable under basic intestinal pH conditions. The instability in the intestine, combined with a high water solubility, makes very difficult to formulate modified release systems of captopril. As the result of the bibliographic research carried out in this thesis, controlled release matrix tablets of captopril have been developed by direct compression with the aim to retain the dosage form in the stomach in order to ensure an optimal stability during the release of captopril. The research of this work has consisted in the preparation of formulations with different dissolution profiles applying the methodology Quality by Design (QbD) and their characterization using the SeDeM diagram, and microscopic techniques that have been used for the first time in the characterization of hydrophilic matrix tablets. The methodology used has been the combination of a very comprehensive bibliographic search and with the use of advanced microscopic techniques (Atomic Force Microscopy, Scanning Electron Microscopy, Contact angle, and Confocal Microscopy), it has been obtained a relationship between the physicochemical parameters of the hydrophilic matrices with the microscopic parameters. The results obtained in this thesis have been the obtaining of methodologies that represent a scientific breakthrough in the characterization of hydrophilic matrices. The results from this research can lead to a wide range of studies in the field of Pharmaceutical Technology, since the concepts acquired are potentially applicable to other drug delivery systems.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Captopril"

1

Beedles, R. Capoten to Captopril, opportunity or threat. Oxford: Oxford Brookes University, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

G, Nicholls M., ed. New concepts in cardiovascular medicine: The developing role of captopril. Auckland, N.Z: ADIS Press, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pierce, Belinda. The radical scavenging properties of two sulphur containing drugs - captopril and thiopurinol. Uxbridge: Brunel University, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nekooeian, Ali Akbar. Acute effects of Ro44-9375, captopril and DuP 532 on hemodynamics and total vascular capacitance in experimental acute heart failure. Ottawa: National Library of Canada, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

K, Ferguson Roger, and Vlasses Peter, eds. Angiotensin-converting enzyme inhibitors. Mount Kisco, N.Y: Futura Pub. Co., 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wehner, Clark. Captopril Stada. Independently Published, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Blokdijk, G. J. Captopril; Second Edition. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Case, David. Captopril and Hypertension. Springer, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Case, David. Captopril and Hypertension. Springer London, Limited, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Driver, Gerald. The effect of captopril on blood glucose control. Bradford, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Captopril"

1

Maxwell, Robert A., and Shohreh B. Eckhardt. "Captopril." In Drug Discovery, 19–34. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0469-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beyer, Karl-Heinz. "Captopril." In Biotransformation der Arzneimittel, 112–13. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74386-3_53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Peter, Helga, and Thomas Penzel. "Captopril." In Springer Reference Medizin, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_378-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schneeweiss, Adam, and Gotthard Schettler. "Captopril." In Developments in Cardiovascular Medicine, 56–69. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-2063-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

de Groot, Anton C. "Captopril." In Monographs In Contact Allergy, 198–200. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-85.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hubl, W. "Captopril-Test." In Springer Reference Medizin, 515–17. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_3662.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hubl, W. "Captopril-Test." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1–2. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-49054-9_3662-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ergin, Ahmet Bahadir, Amir H. Hamrahian, A. Laurence Kennedy, and Manjula K. Gupta. "Captopril Challenge Test." In The Cleveland Clinic Manual of Dynamic Endocrine Testing, 67–70. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13048-4_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Machraoui, A., U. G. Windgassen, and J. Barmeyer. "Hämodynamische Wirkung von Captopril bei Cor pulmonale." In Vasoaktive Substanzen bei Herzinsuffizienz, 201–8. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71486-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stefanović, V., S. Kostić, and M. Bogićević. "Captopril Treatment of Hypertensive Patients on Maintenance Hemodialysis." In New Therapeutic Strategies in Nephrology, 265–67. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3884-4_76.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Captopril"

1

Manabe, Noriyoshi, Akiyoshi Hoshino, Yi-qiang Liang, Tomomasa Goto, Norihiro Kato, and Kenji Yamamoto. "Toward the in vivo study of captopril-conjugated quantum dots." In Biomedical Optics 2005, edited by Alexander N. Cartwright and Marek Osinski. SPIE, 2005. http://dx.doi.org/10.1117/12.601615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pagotto, Laís de Cassia Groppo, and Isabela Rutkowski. "O USO DO CAPTOPRIL SUBLINGUAL NA URGÊNCIA HIPERTENSIVA - HÁ BENEFÍCIOS?" In Anais do II Congresso Nacional de Trauma e Medicina de Emergência. Recife, Brasil: Even3, 2023. http://dx.doi.org/10.29327/1191727.2-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Arinuma, Yoshiyuki, Kenji Oku, and Kunihiro Yamaoka. "LSO-097 Captopril preventing blood brain barrier breach by anti-smith antibody." In The 15th International Congress on Systemic Lupus Erythematosus and The 43rd KCR Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023). Lupus Foundation of America, 2023. http://dx.doi.org/10.1136/lupus-2023-kcr.137.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Sheng-Hung, Wei-Kung Wang, Tse-Lin Hsu, Ming-Yie Jan, and Yuh-Ying Lin Wang. "Effects of Captopril on Specific Harmonic Indexes of the Peripheral Pressure Pulse Waveform." In 2010 4th International Conference on Bioinformatics and Biomedical Engineering (iCBBE). IEEE, 2010. http://dx.doi.org/10.1109/icbbe.2010.5515815.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nieto González, Noelia, Antonella Obinu, Elisabetta Gavini, Paolo Giunchedi, and Giovanna Rassu. "Cellulose acetate phthalate-chitosan based nanoparticles for transdermal delivery of captopril in pediatric patients." In The 1st International Electronic Conference on Pharmaceutics. Basel, Switzerland: MDPI, 2020. http://dx.doi.org/10.3390/iecp2020-08786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

AL-Tikrity, Nadia Y., Firas SH-Abd Ulrazzaq, and Ahmet Beyatli. "Synthesis, biochemical and histological study of captopril derivatives as a possible drug for diabetes." In PROCEEDINGS OF THE 2020 2ND INTERNATIONAL CONFERENCE ON SUSTAINABLE MANUFACTURING, MATERIALS AND TECHNOLOGIES. AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0030689.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Junaidi, Dhati Aulia Sari, and Emil Budianto. "In vitro efficiency test of captopril microencapsulation using polyblend of poly (lactic acid) and polycaprolactone." In THE 3RD INTERNATIONAL SEMINAR ON CHEMISTRY: Green Chemistry and its Role for Sustainability. Author(s), 2018. http://dx.doi.org/10.1063/1.5082451.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jalili, Majid, and Hamid Sarbazi-Azad. "Captopril: Reducing the Pressure of Bit Flips on Hot Locations in Non-Volatile Main Memories." In Proceedings of the 2016 Design, Automation & Test in Europe Conference & Exhibition (DATE). Singapore: Research Publishing Services, 2016. http://dx.doi.org/10.3850/9783981537079_0032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Koh, Shir Lin, E. I. Ager, C. Malcontenti-Wilson, P. L. Costa, V. Muralidharan, and C. Christophi. "Abstract 3707: Captopril inhibits colorectal cancer liver metastases following 70% partial hepatectomy in a mouse model." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3707.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Molthen, Robert, Qingping Wu, Shelley Baumgardt, Laura Kohlhepp, Rahul Shingrani, and Gary Krenz. "Arterial morphology responds differently to Captopril then N-acetylcysteine in a monocrotaline rat model of pulmonary hypertension." In SPIE Medical Imaging, edited by Robert C. Molthen and John B. Weaver. SPIE, 2010. http://dx.doi.org/10.1117/12.844830.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Captopril"

1

Bonfante-Cabarcas, Rafael Armando, Hubert Hernández, Angelina Docimo Cilio, Juan Luis Concepción, Claudina del Carmen Rodríguez - Bonfante, Jaime Marín, Yusra Al Atrache Gratrif, and Martha Silva Falcon. El Captopril Disminuye los Valores de Proteína C-Reactiva en la Enfermedad de Chagas. Buenos Aires: siicsalud.com, March 2017. http://dx.doi.org/10.21840/siic/153339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Captopril' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography